Cargando…
MOLECULAR PROFILING TO UNDERSTAND TREATMENT RESISTANCE AND RESPONSE IN GLIOBLASTOMA
Patients with glioblastoma experience a wide variation in response to standard treatment, with nearly 30% experiencing tumour progression during treatment, and nearly 7% surviving more than 5 years. CEST-MRI is sensitive to treatment-induced changes in tumour metabolism and can be used to evaluate t...
Autores principales: | Nikolopoulos, Marina, Wu, Megan, Bahcheli, Alexander, Kellett, Sorcha, Erickson, Anders, Myrehaug, Sten, Sahgal, Arjun, Spears, Melanie, Bayani, Jane, Das, Sunit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337568/ http://dx.doi.org/10.1093/noajnl/vdad071.040 |
Ejemplares similares
-
Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy
por: Mehrabian, Hatef, et al.
Publicado: (2018) -
RE-IRRADIATION FOR RECURRENT HIGH-GRADE GLIOMA: AN ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL AND PREDICTORS OF RADIATION NECROSIS
por: Moore-Palhares, Daniel, et al.
Publicado: (2023) -
Improved dosimetric accuracy with semi‐automatic contour propagation of organs‐at‐risk in glioblastoma patients undergoing chemoradiation
por: Lee, Sangjune, et al.
Publicado: (2019) -
Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020) -
PREDICTORS OF TUMOR DYNAMICS DURING A COURSE OF 30-FRACTION RADIOTHERAPY FOR GLIOBLASTOMA
por: Ong, W L, et al.
Publicado: (2023)